You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 256 No. 9, September 5, 1986 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (38)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Adjuvant Chemotherapy for Breast Cancer

A Pooled Estimate Based on Published Randomized Control Trials

Harvey N. Himel, MD, MPH; Alessandro Liberati, MD; Richard D. Gelber, PhD; Thomas C. Chalmers, MD

JAMA. 1986;256(9):1148-1159.


Abstract

The use of adjuvant chemotherapy for treating patients with operable breast cancer remains a worldwide controversy. Using the data from published randomized control trials with a minimum two-year follow-up, pooled estimates of relapse-free survival rates and overall survival rates were calculated. Relapse-free survival rates were improved by 12.5% (95% confidence interval [CI] ±4.5%) at three years and by 8% (CI ±6%) at five years, with studies using multiple agents showing a greater effect. A significant advantage was also present in overall survival rates at three years, but only for studies involving multiple agents (4% ±3.5%). Results from combining data for other types of trials were inconclusive. The use of this method is presented to illustrate its value as an explicit and systematic one for combining data from several randomized control trials in assessing a therapeutic controversy.

(JAMA 1986;256:1148-1159)



Author Affiliations

From the Departments of Health Policy & Management (Drs Himel and Chalmers), Epidemiology (Dr Liberati), and Biostatistics (Dr Gelber), Harvard School of Public Health, Boston; the Department of Biostatistics, Dana-Farber Cancer Institute (Dr Gelber), Boston; and the Clinical Trials Unit, Mount Sinai School of Medicine, New York (Dr Chalmers).


Footnotes

Reprint requests to Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029 (Dr Chalmers).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Review of Mortality From Choroidal Melanoma: II. A Meta-Analysis of 5-Year Mortality Rates Following Enucleation, 1966 Through 1988
Diener-West et al.
Arch Ophthalmol 1992;110:245-250.
ABSTRACT  

Meta-analysis: A Quantitative Approach to Research Integration
Thacker
JAMA 1988;259:1685-1689.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.